Lescarden expands ICN deal to cover Canada:
This article was originally published in Clinica
ICN Canada, of Montreal, Quebec, has been granted a 10-year exclusive licence to market New York-based Lescarden's Catrix wound dressing in Canada. The product, which is a specially processed bovine cartilage product in fine-powder form, is FDA-approved for the management of chronic skin wounds including decubitus ulcers, venous stasis ulcers and diabetic ulcers, as well as second degree burns and post-radiation dermatitis. The total market is estimated at some $10bn worldwide. ICN Iberica already sells the product in Spain and Portugal.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.